These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 37368200)
1. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia. Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Martínez Banaclocha H; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A Clin Transl Oncol; 2024 Jan; 26(1):278-287. PubMed ID: 37368200 [TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia. Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Banaclocha HM; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A Clin Transl Oncol; 2023 May; 25(5):1446-1454. PubMed ID: 36598635 [TBL] [Abstract][Full Text] [Related]
3. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830 [TBL] [Abstract][Full Text] [Related]
4. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study. Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959 [TBL] [Abstract][Full Text] [Related]
5. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia. Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122 [TBL] [Abstract][Full Text] [Related]
6. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia. Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464 [TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene. Sun YQ; Li SQ; Zhao XS; Chang YJ Expert Rev Anticancer Ther; 2020 Jun; 20(6):453-464. PubMed ID: 32459519 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing. Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930 [TBL] [Abstract][Full Text] [Related]
9. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease. Momen N; Tario J; Fu K; Qian YW J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444 [TBL] [Abstract][Full Text] [Related]
10. Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review. Health Quality Ontario Ont Health Technol Assess Ser; 2016; 16(7):1-52. PubMed ID: 27099643 [TBL] [Abstract][Full Text] [Related]
11. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study. Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R; Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877 [TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction. Cheng SH; Lau KM; Li CK; Chan NP; Ip RK; Cheng CK; Lee V; Shing MM; Leung AW; Ha SY; Cheuk DK; Lee AC; Li CH; Luk CW; Ling SC; Hrusak O; Mejstrikova E; Leung Y; Ng MH PLoS One; 2013; 8(7):e69467. PubMed ID: 23936021 [TBL] [Abstract][Full Text] [Related]
13. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599 [TBL] [Abstract][Full Text] [Related]
14. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry]. Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543 [TBL] [Abstract][Full Text] [Related]
15. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements. Popov A; Tsaur G; Verzhbitskaya T; Riger T; Permikin Z; Demina A; Mikhailova E; Shorikov E; Arakaev O; Streneva O; Khlebnikova O; Makarova O; Miakova N; Fominikh V; Boichenko E; Kondratchik K; Ponomareva N; Novichkova G; Karachunskiy A; Fechina L Br J Haematol; 2023 May; 201(3):510-519. PubMed ID: 34970734 [TBL] [Abstract][Full Text] [Related]
16. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444 [TBL] [Abstract][Full Text] [Related]
17. Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia. Wang ZD; Wang YW; Xu LP; Zhang XH; Wang Y; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Wang YZ; Liu YR; Liu KY; Huang XJ; Chang YJ Curr Med Sci; 2021 Jun; 41(3):443-453. PubMed ID: 34185250 [TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry]. Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430 [TBL] [Abstract][Full Text] [Related]
19. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517 [TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]